Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Lymphoid 3Genitourinary 3CNS 3Other hematologic neoplasm 2Sarcoma 1Plasma cell 1Dermatologic 1Breast 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × motexafin gadolinium × Plasma cell × Clear all
NCT00096837 2006-06-08

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Pharmacyclics LLC.

Phase 2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡